Cytomegalovirus Antibody - BSA Free
Novus Biologicals, part of Bio-Techne | Catalog # NB100-65055
Key Product Details
Species Reactivity
Cytomegalovirus, Virus
Applications
Immunohistochemistry, Immunohistochemistry-Frozen, Western Blot, ELISA
Label
Unconjugated
Antibody Source
Polyclonal Goat IgG
Format
BSA Free
Concentration
4.0-5.0 mg/ml
Product Specifications
Immunogen
Purified virons of strain AD169
Specificity
Predominant reactivity is to glycoprotein B.
Clonality
Polyclonal
Host
Goat
Isotype
IgG
Applications for Cytomegalovirus Antibody - BSA Free
Application
Recommended Usage
ELISA
1:100-1:2000
Immunohistochemistry
1:10-1:500
Immunohistochemistry-Frozen
1:10-1:500
Western Blot
1:100-1:2000
Formulation, Preparation, and Storage
Purification
IgG purified
Formulation
PBS
Format
BSA Free
Preservative
0.1% Sodium Azide
Concentration
4.0-5.0 mg/ml
Shipping
The product is shipped with polar packs. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage
Store at 4C short term. Aliquot and store at -20C long term. Avoid freeze-thaw cycles.
Background: Cytomegalovirus
Cytomegalovirus is a common virus, infecting ~60% of adults in developed countries and over 90% in developing countries, as indicated by presence of specific IgG antibodies (2-4). Although a majority of people infected remain asymptomatic, immunocompromised people, organ transplant recipients, and fetuses and newborns are more susceptible to HCMV-associated diseases (1-4). Annually, up to 2% of newborns are born with HCMV, making it the most common congenital infection (2-4). Cytomegalovirus is known to cause sensorineural hearing loss (SNHL), mental retardation, chorioretinitis, skin lesions, as well as end organ disease (3,5). There are a few CMV therapeutics approved by FDA including valganciclovir and letermovir; however, despite some benefits, there is the need for new antivirals and combination therapies (5). Potential new treatment options include monoclonal antibodies and sirtuins (5).
References
1. Connolly SA, Jardetzky TS, Longnecker R. The structural basis of herpesvirus entry. Nat Rev Microbiol. 2021;19(2):110-121. https://doi.org/10.1038/s41579-020-00448-w
2. Griffiths P, Reeves M. Pathogenesis of human cytomegalovirus in the immunocompromised host. Nat Rev Microbiol. 2021;19(12):759-773. https://doi.org/10.1038/s41579-021-00582-z
3. Krstanovic F, Britt WJ, Jonjic S, Brizic I. Cytomegalovirus Infection and Inflammation in Developing Brain. Viruses. 2021;13(6):1078. Published 2021 Jun 4. https://doi.org/10.3390/v13061078
4. Griffiths P, Baraniak I, Reeves M. The pathogenesis of human cytomegalovirus. J Pathol. 2015;235(2):288-297. https://doi.org/10.1002/path.4437
5. Acosta E, Bowlin T, Brooks J, et al. Advances in the Development of Therapeutics for Cytomegalovirus Infections. J Infect Dis. 2020;221(Suppl 1):S32-S44. https://doi.org/10.1093/infdis/jiz493
Alternate Names
CMV; HHV 5; HHV5; Human herpesvirus 5
UniProt
Additional Cytomegalovirus Products
Product Documents for Cytomegalovirus Antibody - BSA Free
Product Specific Notices for Cytomegalovirus Antibody - BSA Free
This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.
Loading...
Loading...
Loading...
Loading...